Home › Funds › PFM Health Sciences, LP › CYTK
PFM Health Sciences, LP position in CYTK
CYTOKINETICS INC COM NEW · Health Care
PFM Health Sciences, LP reported holding 191,686 shares of CYTK (CYTOKINETICS INC COM NEW) in its Q2 2026 13F filing — a position valued at US$16.3M, representing 1.43% of its reported portfolio and ranking #21 among its reported holdings. PFM Health Sciences, LP has disclosed CYTK holdings in 6 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How PFM Health Sciences, LP's CYTK position evolved
PFM Health Sciences, LP first disclosed a stake in CYTK in Q3 2023 at 25,000,000 shares (US$21.3M). The position peaked in Q2 2024 at 1,757,192 shares, worth US$95.2M. Across 6 filings, PFM Health Sciences, LP increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 191,686 shares valued at US$16.3M. Notable position changes include a 68% trim in Q4 2023 (shares fell 16% over the following quarter), a 76% trim in Q2 2024 (shares fell 3% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 25.00M | $21.33M | New |
| Q4 2023 | 8.00M | $14.09M | Reduce |
| Q1 2024 | 7.20M | $11.45M | Reduce |
| Q2 2024 | 1.76M | $95.20M | Reduce |
| Q3 2024 | 1.76M | $92.78M | Hold |
| Q2 2026 | 191.69K | $16.33M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CYTK and 13F data
CYTK (CYTOKINETICS INC COM NEW) is a Health Care company. 52 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.72M sh · $1.59B · Q2 2026
- Avoro Capital Advisors LLC 5.00M sh · $425.95M · Q2 2026
- RTW INVESTMENTS, LP 2.86M sh · $243.81M · Q2 2026
- Polar Capital Holdings Plc 2.25M sh · $191.99M · Q2 2026
- Integral Health Asset Management, LLC 1.60M sh · $136.30M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.20M sh · $102.34M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.16M sh · $98.81M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 980.39K sh · $83.52M · Q2 2026
- GW&K Investment Management, LLC 916.11K sh · $78.04M · Q2 2026
- Melqart Asset Management (UK) Ltd 767.52K sh · $65.39M · Q2 2026
- Siren, L.L.C. 758.95K sh · $64.66M · Q2 2026
- Foresite Capital Management IV, LLC 714.70K sh · $60.88M · Q2 2026
More on PFM Health Sciences, LP
FAQ
How long has PFM Health Sciences, LP held CYTK?
PFM Health Sciences, LP has disclosed CYTK holdings in 6 of the last 12 reported quarters, going back to Q3 2023.
What is PFM Health Sciences, LP's current position in CYTK?
As of Q2 2026, PFM Health Sciences, LP holds 191.69K shares of CYTK (CYTOKINETICS INC COM NEW), valued at $16.33M, representing 1.43% of its reported portfolio and ranking #21.
Has PFM Health Sciences, LP been buying or selling CYTK?
In the latest 13F filing (Q2 2026), PFM Health Sciences, LP newly opened its position in CYTK. The position peaked in Q2 2024 at 1.76M shares.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.